Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

@article{Deangelo2007NelarabineIC,
  title={Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.},
  author={Daniel J. Deangelo and Daohai Yu and Jeffrey R. Johnson and Steven E. Coutr{\'e} and Richard M Stone and Alison T Stopeck and Jon P. Gockerman and Beverly S. Mitchell and Frederick R Appelbaum and Richard A Larson},
  journal={Blood},
  year={2007},
  volume={109 12},
  pages={5136-42}
}
Nelarabine (506U78) is a soluble pro-drug of 9-beta-D-arabinofuranosylguanine (ara-G), a deoxyguanosine derivative. We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine. All patients were refractory to at least one multiagent regimen or had relapsed after achieving a complete remission. Nelarabine was administered on an alternate day schedule (days 1, 3, and 5) at 1.5 g/m(2)/day. Cycles were repeated every 22… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 74 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

mary refractory and relapsed adult acute lymphoblastic leukemia : characteristics , treatment results , and prognosis with salvage therapy

  • CU Lambe, DR Averett, MT Paff, JE Reardon, JG Wilson, TA Krenitsky
  • Cancer
  • 1999

Similar Papers

Loading similar papers…